// App-Quantinova.ai

: Artificial intelligence (AI)-powered immune phenotyping to predict outcomes of immuno-oncology (IO)-based regimens in hepatocellular carcinoma (HCC).

Researchers

Presenter

  • Hongjae Chon

Principal Investigators

  • Chan Kim

  • Beodeul Kang

  • Jaekyung Cheon

  • Gwangil Kim

  • Chiyoon Oum

  • Seulki Kim

  • Gahee Park

  • Mohammad Mostafavi

  • Mingu Kang

  • Chan-Young Ock

Medical Centers

  • Lunit Inc., Seoul, South Korea

  • Department of Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea

  • Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea

  • CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea

Locations

  • Republic of South Korea

Companies

  • Lunit Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Atezolizumab

  • Bevacizumab

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved